2nd Oct 2009 10:58
|
For immediate release |
2 October2009 |
ABCAM PLC
("Abcam" or "the Company")
Annual Report & Accounts
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that its Annual Report and Accounts for the year ended 30 June 2009 has been posted to shareholders and is available at the Company's investor relations website, www.abcamplc.com.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA and Tokyo, Japan. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 55,000 products, most of which are antibodies, from over 250 suppliers and employs 237 staff in its three operating companies.
About antibodies
Antibodies are proteins produced by white blood cells in response to the introduction of a foreign body known as an antigen. Antibodies, which have a wide variety of uses in research, diagnostics and therapeutics, are used by bioscientists in research into disease and into the human genome, where they are used to mark and identify specific cells and other living matter. The number of human antibodies of use in research is potentially greater than one million.
Related Shares:
ABC.L